24/02/2009 (Agence Europe) - On Thursday 19 February, the European Medicines Agency recommended that vaccination should be continued against papillomavirus (HPV), the cause of cervical cancer, using the Gardasil vaccine developed by MSD of the United States and marketed in 19 countries of Europe by Sanofi Pasteur MSD. The Agency considers that the benefit/risk ratio of administering the vaccine remains favourable even after two cases of convulsion and loss of consciousness of an epileptic...